AI Article Synopsis
- A case study discusses the treatment of unilateral macular edema in a 16-year-old boy with Wyburn-Mason syndrome, using Bevacizumab and Aflibercept.
- After an initial treatment with Bevacizumab proved ineffective, the patient showed significant improvement with Aflibercept after three monthly injections.
- The study suggests that Aflibercept may be a safe and effective alternative for managing macular edema resulting from retinal arteriovenous malformations.
Article Abstract
Purpose: Macular edema is an infrequent complication of retinal arteriovenous malformations. We present the management of unilateral macular edema with Bevacizumab 1.25mg/0.05mL and Aflibercept 2mg/0.05mL in a 16-year-old child with Wyburn-Mason syndrome.
Observations: The patient developed macular edema after 15 years of unremarkable ophthalmological follow-up. After a one-month observation period, a first intravitreal injection of Bevacizumab 1.25mg/0.05mL, the treatment most frequently described in the literature, was found to be insufficient to reduce the macular edema.After the switch to Aflibercept 2.0mg/0.05mL, a significant reduction in macular edema was observed after three monthly intravitreal injections. This effect was prolonged over the 15-month observation follow-up.
Conclusions And Importance: Aflibercept 2mg/0.05mL may be a safe and effective option to manage macular edema complications in retinal arteriovenous malformations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635018 | PMC |
| http://dx.doi.org/10.1016/j.ajoc.2024.102209 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced Ocular Bioavailability and Prolonged Duration via Hydrophilic Surface Nanocomposite Vesicles for Topical Drug Administration.
Pharmaceutics
November 2024
Guangdong Provincial Key Laboratory of Advanced Drug Delivery, Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Guangdong Pharmaceutical University, No. 280 University Town Outer Ring East Road, Guangzhou 510006, China.
Background: Internal ocular diseases, such as macular edema, uveitis, and diabetic macular edema require precise delivery of therapeutic agents to specific regions within the eye. However, the eye's complex anatomical structure and physiological barriers present significant challenges to drug penetration and distribution. Traditional eye drops suffer from low bioavailability primarily due to rapid clearance mechanisms.
View Article and Find Full Text PDFAnti-Vascular Endothelial Growth Factor Combined with Ocular Steroid Therapy for Persistent Diabetic Macular Edema: A Systematic Review and Meta-Analysis.
Pharmaceuticals (Basel)
November 2024
Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Road, Wuhan 430030, China.
: Our purpose was to appraise the efficacy and safety of intravitreous vascular endothelial growth factor inhibitor (anti-VEGF) therapy combined with steroids for persistent diabetic macular edema. : A systematic review was conducted of the research evaluating the combination therapy of anti-VEGF and steroids for persistent diabetic macular edema compared to anti-VEGF alone. A meta-analysis was performed using a protocol registered in PROSPERO (CRD42023476333).
View Article and Find Full Text PDFCharacteristics of Microaneurysm Size in Residual Edema After Intravitreal Injection of Faricimab for Diabetic Macular Edema.
J Clin Med
December 2024
Department of Ophthalmology, Faculty of Medical Sciences, University of Fukui, Eiheiji-cho, Yoshida-gun, Fukui-ken 910-1193, Fukui, Japan.
Microaneurysms (MAs) are important in the pathology of diabetic macular edema (DME) and its response to anti-vascular endothelial growth factor (VEGF) therapy. This study aimed to clarify the morphological characteristics of MAs in residual edema following consecutive faricimab injections, a bispecific antibody against angiopoietin-2 and VEGF. We selected patients with DME who exhibited residual edema after three monthly injections of faricimab.
View Article and Find Full Text PDFEvaluation of Ocular and Systemic Oxidative Stress Markers in Patients with Diabetic Retinopathy.
Life (Basel)
December 2024
Institute of Clinical and Experimental Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.
Proliferative diabetic retinopathy (PDR) is the most severe complication of chronic hyperglycaemi stimulates oxidative stress that changes the retinal basement membrane function and provokes neovascularization, macular edema and retinal detachment. But an oxidative-antioxidant biomarker assessment in ocular matrices, such as aqueous humor (AH) and vitreous, might show the oxidative stress (OS) status in the posterior segment. Here, we show a cross-sectional analytical study of 39 patients who had a vitrectomy and assess the levels of different oxidative-antioxidant biomarkers in blood, aqueous and vitreous humor in three groups: diabetes mellitus 2 (DM2) with PDR [DM(+)PDR(+)] ( =13), DM2 without PDR [DM(+)PDR(-)] ( = 13) and non-DM2 non-PDR [DM(-)PDR(-)] as the control group ( = 13).
View Article and Find Full Text PDFBrolucizumab for the Treatment of Diabetic Macular Edema: An Optical Coherence Tomography-Based Analysis.
Diagnostics (Basel)
December 2024
Eye Clinic, Department of Medical, Surgical Sciences and Health, University of Trieste, 34127 Trieste, Italy.
: The objectives of this study were to evaluate the structural and functional outcomes after the loading phase with brolucizumab in switched patients with diabetic macular edema (DME) and to identify potential predictive biomarkers of treatment response. : A total of 28 eyes with DME, switched to brolucizumab, were retrospectively reviewed. Main outcomes during the follow-up period, up to 6 weeks after the fifth injection, included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), macular volume, subfoveal choroidal thickness, intraretinal and subretinal fluid (IRF and SRF), cyst dimension including maximal horizontal cyst diameter (MHCD), maximal vertical cyst diameter (MVCD), width-to-height ratio (WHR), foveal avascular zone (FAZ) dimension, and vessel density (VD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!